The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer
Janna R. Shapiro Mario Corrado Julie Perry Tania H. Watts Shelly Bolotin a Department of Immunology,Temerty Faculty of Medicine,University of Toronto,Toronto,ON,Canadab Center for Vaccine Preventable Diseases,Dalla Lana School of Public Health,University of Toronto,Toronto,ON,Canadac Division of General Internal Medicine,University of Toronto,Toronto,ON,Canadad Department of Laboratory Medicine and Pathobiology,Temerty Faculty of Medicine,University of Toronto,Toronto,ON,Canadae Department of Health Protection,Public Health Ontario,Toronto,ON,CanadaDr. Shelly Bolotin is the Director of the Centre for Vaccine Preventable Diseases,and an Associate Professor at the Dalla Lana School of Public Health and the Department of Laboratory Medicine and Pathobiology,at the University of Toronto. She is also a Scientist at Public Health Ontario. Her research program utilizes a multi-disciplinary approach to evaluate whether our population is adequately protected from vaccine-preventable diseases. Applying a public health lens,Shelly's studies combine epidemiological and microbiological methods to answer questions related to population immunity and vaccine effectiveness,and determine our future risk for outbreaks or epidemics.
DOI: https://doi.org/10.1080/21645515.2024.2395679
2024-08-31
Human Vaccines & Immunotherapeutics
Abstract:In the face of the ever-present burden of emerging and reemerging infectious diseases, there is a growing need to comprehensively assess individual- and population-level immunity to vaccine-preventable diseases (VPDs). Many of these efforts, however, focus exclusively on antibody-mediated immunity, ignoring the role of T cells. Aimed at clinicians, public health practioners, and others who play central roles in human vaccine research but do not have formal training in immunology, we review how vaccines against infectious diseases elicit T cell responses, what types of vaccines elicit T cell responses, and how T cell responses are measured. We then use examples to demonstrate six ways that T cells contribute to protection from VPD, including directly mediating protection, enabling antibody responses, reducing disease severity, increasing cross-reactivity, improving durability, and protecting special populations. We conclude with a discussion of challenges and solutions to more widespread consideration of T cell responses in clinical vaccinology.
immunology,biotechnology & applied microbiology